OBJECTIVE: To perform a systematic review and meta-analysis of human studies on the association between serum 25 hydroxyvitamin D (25(OH)D) and incident, sporadic colorectal adenoma (CRA) and CRA recurrence. METHODS: Relevant studies among humans were identified by systematically searching Ovid Medline, EMBASE, and ISI Web of Knowledge databases and by cross-referencing. Due to the heterogeneity across studies in categorizing serum vitamin D levels, all results were recalculated for an increase of serum 25(OH)D by 20 ng/ml. Summary odds ratios (ORs) were calculated using meta-analysis methods. RESULTS: Overall, 10 original studies were included. Specific results for incident CRA according to serum 25(OH)D were reported in 8 studies, and for CRA recurrence in 2 studies, respectively. In meta-analyses, summary ORs (95% confidence intervals) regarding incident and recurrent CRA, and both outcomes combined were 0.82 (0.69-0.97), 0.87 (0.56-1.35), and 0.84 (0.72-0.97), respectively, for an increase of 25(OH)D by 20 ng/ml. No publication bias was found. CONCLUSION: Our results support suggestions that serum 25(OH)D levels are inversely associated with CRA risk. Crown
OBJECTIVE: To perform a systematic review and meta-analysis of human studies on the association between serum 25 hydroxyvitamin D (25(OH)D) and incident, sporadic colorectal adenoma (CRA) and CRA recurrence. METHODS: Relevant studies among humans were identified by systematically searching Ovid Medline, EMBASE, and ISI Web of Knowledge databases and by cross-referencing. Due to the heterogeneity across studies in categorizing serum vitamin D levels, all results were recalculated for an increase of serum 25(OH)D by 20 ng/ml. Summary odds ratios (ORs) were calculated using meta-analysis methods. RESULTS: Overall, 10 original studies were included. Specific results for incident CRA according to serum 25(OH)D were reported in 8 studies, and for CRA recurrence in 2 studies, respectively. In meta-analyses, summary ORs (95% confidence intervals) regarding incident and recurrent CRA, and both outcomes combined were 0.82 (0.69-0.97), 0.87 (0.56-1.35), and 0.84 (0.72-0.97), respectively, for an increase of 25(OH)D by 20 ng/ml. No publication bias was found. CONCLUSION: Our results support suggestions that serum 25(OH)D levels are inversely associated with CRA risk. Crown
Authors: María Elena Martínez; Elizabeth T Jacobs; John A Baron; James R Marshall; Tim Byers Journal: J Natl Cancer Inst Date: 2012-04-25 Impact factor: 13.506
Authors: Paulette D Chandler; Julie E Buring; JoAnn E Manson; Edward L Giovannucci; M V Moorthy; Shumin Zhang; I-Min Lee; Jennifer H Lin Journal: Cancer Prev Res (Phila) Date: 2015-03-26
Authors: John A Baron; Elizabeth L Barry; Leila A Mott; Judy R Rees; Robert S Sandler; Dale C Snover; Roberd M Bostick; Anastasia Ivanova; Bernard F Cole; Dennis J Ahnen; Gerald J Beck; Robert S Bresalier; Carol A Burke; Timothy R Church; Marcia Cruz-Correa; Jane C Figueiredo; Michael Goodman; Adam S Kim; Douglas J Robertson; Richard Rothstein; Aasma Shaukat; March E Seabrook; Robert W Summers Journal: N Engl J Med Date: 2015-10-15 Impact factor: 91.245
Authors: Christoph Amadeus Agten; Lukas Margaroli; Susanne Bensler; Benjamin Fritz; Andrea B Rosskopf; Ulrike Held; Christian W A Pfirrmann Journal: Skeletal Radiol Date: 2018-02-02 Impact factor: 2.199
Authors: Vincent T Janmaat; Anouk Van De Winkel; Maikel P Peppelenbosch; Manon C W Spaander; André G Uitterlinden; Farzin Pourfarzad; Hugo W Tilanus; Agnieszka M Rygiel; Leon M G Moons; Pascal P Arp; Kausilia K Krishnadath; Ernst J Kuipers; Luc J W Van Der Laan Journal: Mol Med Date: 2015-04-21 Impact factor: 6.354
Authors: Audrey H Calderwood; John A Baron; Leila A Mott; Dennis J Ahnen; Roberd M Bostick; Jane C Figueiredo; Michael N Passarelli; Judy R Rees; Douglas J Robertson; Elizabeth L Barry Journal: Cancer Prev Res (Phila) Date: 2019-03-04